Home » Topics » Infection, BioWorld Science

Infection, BioWorld Science
RSS

XVR-011 shows neutralization activity against the Gamma and Delta variants of SARS-CoV-2

July 14, 2021

AR-712 MAb cocktail neutralizes SARS-CoV-2 Delta variant

July 14, 2021

VRG-101: a new PIKfyve inhibitor for SARS-CoV-2

July 14, 2021

FDA clears Tevogen Bio's IND application for TVGN-489 for COVID-19

July 13, 2021

Safety and immunogenicity of BNT-162b1 confirmed in phase I study in Chinese adults

July 13, 2021

Vaccibody and Adaptive Biotechnologies sign license agreement on SARS-CoV-2 T-cell epitopes

July 13, 2021

Patients dosed in phase I/II trial of topical RECCE-327 for infected burn wounds

July 13, 2021

Aptorum reports further interim phase I data on ALS-4

July 13, 2021

Identification of antivirulence compound ANT-3273 for P. aeruginosa infection

July 13, 2021

Condensate drugs block RSV replication in vivo

July 13, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...